{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280669","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.173167+00:00","generated_at":"2026-06-22T01:14:07.822255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end","bullets":["Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.","NDA for avasopasem in radiotherapy-induced severe oral mucositis remains on track for submission by end of 2022.","One-year ROMAN follow-up showed tumor outcomes and overall survival maintained; 50% reduction in chronic kidney disease (10% vs 20% placebo, p=0.0043).","Meta-analysis of ROMAN and GT-201 (n=551) showed reductions in SOM incidence, duration, onset, and severity.","Appointed Eugene P. Kennedy, M.D., as Chief Medical Officer, succeeding Jon T. Holmlund who plans to retire."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280669","json":"https://secwatch.observer/filing/0001193125-22-280669.json","markdown":"https://secwatch.observer/filing/0001193125-22-280669.md","text":"https://secwatch.observer/filing/0001193125-22-280669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/0001193125-22-280669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/d419294d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:14:07.822255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cafe3fc72d32cb649657602e0db4d5200daf585b","claim":"Galera Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income ($16.0) million, or $(0.60) per share, EPS $(0.60) per share.","evidence_excerpt":"Galera reported a net loss of ($16.0) million, or $(0.60) per share, for the third quarter of 2022, compared to a net loss of $(22.6) million, or $(0.86) per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522280669/0001193125-22-280669-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"($16.0) million, or $(0.60) per share"},{"label":"EPS","value":"$(0.60) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}